Dichotomous effects of IFN-γ on dendritic cell function determine the extent of IL-12 - driven antitumor T cell immunity

Journal of Immunology

Volumn 187, Issue 1, 2011, Pages 126-132

  Harden, Jamie L ^a   Gu, Tao ^a   Kilinc, Mehmet O ^a   Rowswell Turner, Rachael B ^a   Virtuoso, Lauren P ^a   Egilmez, Nejat K ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLTRYPTOPHAN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 12; TRANSCRIPTION FACTOR FOXP3; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ FOXP3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; ENZYME INHIBITION; FEEDBACK SYSTEM; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOMODULATION; LUNG ALVEOLUS CELL CARCINOMA; LYMPH NODE; MALE; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; COCULTURE TECHNIQUES; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-12; LUNG NEOPLASMS; LYMPH NODES; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; PULMONARY ALVEOLI; T-LYMPHOCYTE SUBSETS; TUMOR ESCAPE;

EID: 79960420765     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100168     Document Type: Article

References (38)

1. Dougan, M., and G. Dranoff. 2009. Immune therapy for cancer. Annu. Rev. Immunol. 27: 83-117.
2. Monsurrò, V., E. Wang, Y. Yamano, S. A. Migueles, M. C. Panelli, K. Smith, D. Nagorsen, M. Connors, S. Jacobson, and F. M. Marincola. 2004. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 104: 1970-1978.
3. Rosenberg, S. A., R. M. Sherry, K. E. Morton, W. J. Scharfman, J. C. Yang, S. L. Topalian, R. E. Royal, U. Kammula, N. P. Restifo, M. S. Hughes, et al. 2005. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J. Immunol. 175: 6169-6176. (Pubitemid 41508105)
4. Mantovani, A., P. Romero, A. K. Palucka, and F. M. Marincola. 2008. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371: 771-783.
5. Whiteside, T. L. 2008. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912.
6. Peggs, K. S., S. A. Quezada, and J. P. Allison. 2008. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol. Rev. 224: 141-165.
7. Curran, M. A., W. Montalvo, H. Yagita, and J. P. Allison. 2010. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 107: 4275-4280.
8. Hill, H. C., T. F. Conway, Jr., M. S. Sabel, Y. S. Jong, E. Mathiowitz, R. B. Bankert, and N. K. Egilmez. 2002. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 62: 7254-7263.
9. Nair, R. E., Y. S. Jong, S. A. Jones, A. Sharma, E. Mathiowitz, and N. K. Egilmez. 2006. IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J. Immunother. 29: 10-20.
10. Gu, T., R. B. Rowswell-Turner, M. O. Kilinc, and N. K. Egilmez. 2010. Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. Cancer Res. 70: 129-138.
11. Kilinc, M. O., K. S. Aulakh, R. E. Nair, S. A. Jones, P. Alard, M. M. Kosiewicz, and N. K. Egilmez. 2006. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J. Immunol. 177: 6962-6973.
12. Kilinc, M. O., T. Gu, J. L. Harden, L. P. Virtuoso, and N. K. Egilmez. 2009. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity. J. Immunol. 182: 4217-4225.
13. Kilinc, M. O., R. B. Rowswell-Turner, T. Gu, L. P. Virtuoso, and N. K. Egilmez. 2009. Activated CD8+ T-effector/memory cells eliminate CD4+ CD25+ Foxp3+ T-suppressor cells from tumors via FasL mediated apoptosis. J. Immunol. 183: 7656-7660.
14. Nair, R. E., M. O. Kilinc, S. A. Jones, and N. K. Egilmez. 2006. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors. J. Immunol. 176: 7325-7334.
15. Sercan, O{combining double acute accent}., G. J. Hämmerling, B. Arnold, and T. Schüler. 2006. Innate immune cells contribute to the IFN-γ-dependent regulation of antigen-specific CD8+ T cell homeostasis. J. Immunol. 176: 735-739.
16. Berner, V., H. Liu, Q. Zhou, K. L. Alderson, K. Sun, J. M. Weiss, T. C. Back, D. L. Longo, B. R. Blazar, R. H. Wiltrout, et al. 2007. IFN-γ mediates CD4+ Tcell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat. Med. 13: 354-360.
17. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15: 749-795.
18. Steinman, R. M. 2007. Dendritic cells: understanding immunogenicity. Eur. J. Immunol. 37(Suppl 1): S53-S60.
19. Schroder, K., P. J. Hertzog, T. Ravasi, and D. A. Hume. 2004. Interferon-γ: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75: 163-189.
20. Jü rgens, B., U. Hainz, D. Fuchs, T. Felzmann, and A. Heitger. 2009. Interferon-γ-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 114: 3235-3243.
21. Kirberg, J., A. Baron, S. Jakob, A. Rolink, K. Karjalainen, and H. von Boehmer. 1994. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180: 25-34.
22. Morgan, D. J., R. Liblau, B. Scott, S. Fleck, H. O. McDevitt, N. Sarvetnick, D. Lo, and L. A. Sherman. 1996. CD8(+) T cell-mediated spontaneous diabetes in neonatal mice. J. Immunol. 157: 978-983.
23. Braun, D., R. S. Longman, and M. L. Albert. 2005. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106: 2375-2381.
24. Curtsinger, J. M., and M. F. Mescher. 2010. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol. 22: 333-340.
25. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
26. Jinushi, M., F. S. Hodi, and G. Dranoff. 2008. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol. Rev. 222: 287-298.
27. Puccetti, P. 2007. On watching the watchers: IDO and type I/II IFN. Eur. J. Immunol. 37: 876-879.
28. Sharma, M. D., B. Baban, P. Chandler, D.-Y. Hou, N. Singh, H. Yagita, M. Azuma, B. R. Blazar, A. L. Mellor, and D. H. Munn. 2007. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117: 2570-2582.
29. Belladonna, M. L., C. Volpi, R. Bianchi, C. Vacca, C. Orabona, M. T. Pallotta, L. Boon, S. Gizzi, M. C. Fioretti, U. Grohmann, and P. Puccetti. 2008. Cutting edge: Autocrine TGF-β sustains default tolerogenesis by IDO-competent dendritic cells. J. Immunol. 181: 5194-5198.
30. Matteoli, G., E. Mazzini, I. D. Iliev, E. Mileti, F. Fallarino, P. Puccetti, M. Chieppa, and M. Rescigno. 2010. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut 59: 595-604.
31. Murphy, K. M., and B. Stockinger. 2010. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat. Immunol. 11: 674-680.
32. Ghiringhelli, F., P. E. Puig, S. Roux, A. Parcellier, E. Schmitt, E. Solary, G. Kroemer, F. Martin, B. Chauffert, and L. Zitvogel. 2005. Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4 +CD25+ regulatory T cell proliferation. J. Exp. Med. 202: 919-929.
33. Rutella, S., S. Danese, and G. Leone. 2006. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108: 1435-1440. (Pubitemid 44316106)
34. Morelli, A. E., and A. W. Thomson. 2007. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat. Rev. Immunol. 7: 610-621.
35. Lin, A., A. Schildknecht, L. T. Nguyen, and P. S. Ohashi. 2010. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol. Lett. 127: 77-84.
36. Orabona, C., P. Puccetti, C. Vacca, S. Bicciato, A. Luchini, F. Fallarino, R. Bianchi, E. Velardi, K. Perruccio, A. Velardi, et al. 2006. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 107: 2846-2854.
37. Gough, D. J., D. E. Levy, R. W. Johnstone, and C. J. Clarke. 2008. IFNgamma signaling-does it mean JAK-STAT? Cytokine Growth Factor Rev. 19: 383-394.
38. Gabriele, L., A. Fragale, P. Borghi, P. Sestili, E. Stellacci, M. Venditti, G. Schiavoni, M. Sanchez, F. Belardelli, and A. Battistini. 2006. IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. J. Leukoc. Biol. 80: 1500-1511.